Global Site

Breadcrumb navigation

Japanese

White PaperNEW

-Towards the realization of AI drug development-
Comprehensive process workflow for the commercial use of personalized cancer vaccines

NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.

Outline

  1. A comprehensive process workflow that can be applied to a wide range of processes
  2. Important perspectives for consideration in the workflow
  3. Advanced technologies that will contribute to the realization of the workflow

publication_thumbnail

Downloadnew window

Featured publicationNEW

ESMO2024: Oral DNA vaccination targeting personalised neoantigens in immune checkpoint inhibitor treated solid tumor patients - Interim results

  • Poster Number: 160P
  • Authors: Domas Vaitiekus, E. Juozaityte, L. Puzauskienė, S. Tulyte, L. Gatijatullin, M. Platten, I. Poschke, I.Hulsmeyer, A. Kuhn, A. Aranguren, H. Lubenau, H. Fontenelle, B. Simovski, Y. Yamashita, C.Chaput, A. Meiser, V. Urbonas

Links: new windowPDF of actual poster

publication_thumbnail

Publication / Presentation

Dec 12, 2024
PDFDomas Vaitiekus, E. Juozaityte, L. Puzauskienė, S. Tulyte, L. Gatijatullin, M. Platten, I. Poschke, I.Hulsmeyer, A. Kuhn, A. Aranguren, H. Lubenau, H. Fontenelle, B. Simovski, Y. Yamashita, C.Chaput, A. Meiser, V. Urbonas,"Oral DNA vaccination targeting personalised neoantigens in immune checkpoint inhibitor treated solid tumor patients - Interim results" ESMO Immuno-Oncology Congress, 2024; 160P.NEW
Nov 9, 2024
PDFChristophe Le Tourneau, Jean-Pierre Delord, Ana Lalanne, Camille Jamet, Clementine Spring-Giusti, Annette Tavernaro, Berangere Bastien, Maud Brandely-Talbot, Eric Quemeneur, Kousuke Onoue, Yoshiko Yamashita, Naoko Yamagata, Kazuhide Onoguchi, Ivy Grace Pait, Brandon Malone, Oliver Baker, Per Ludvik Brattas, Olivier Lantz, Kaidre Bendjama, Christian Ottensmeier,"Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)" Society for Immunotherapy of Cancer annual meeting, 2024; 650.NEW
Nov 7, 2024
PDFMartin Renqiang Min, Tianxiao Li, Kazuhide Onoguchi, Daiki Mori, Jonathan Warrell, Pierre Machart, Anja Moesch, Andrea Meiser, Ivy Grace Pait, Ayako Okamura, Daisuke Muraoka, Hirokazu Matsushita, Kaidre Bendjama; "Design of Enhanced TCRs Against Cancer Antigens Using an AI System" SITC. 2024; 1230.NEW
Apr 10, 2024
A. Lalanne, C. Jamet, J.-P. Delord, C. Ottensmeier, C. Le Tourneau, A. Tavernaro, G. Lacoste, B. Bastien, M. Brandely, B. Grellier, E. Quemeneur, Y. Yamashita, O. Kousuke, N. Yamagata, Y. Tanaka, K. Onoguchi, I. Pait, B. Malone, O. Baker, P. Brattas, M. Gheorghe, R. Stratford, T. Clancy, K. Bendjama, O. Lantz; "Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV-negative Head and Neck cancers" AACR. 2024; LB401.
publication_thumbnail
Sep 4, 2023
NEC OncoImmunity to Present Developments in the Infectious Diseases at 21st Awaji International Forum on Infection and Immunity, 2023
Aug 6, 2023
H Komuro, S Shinohara, Y Fukushima, A Demachi-Okamura, D Muraoka, K Masago, T Matsui, Y Sugita, Y Takahashi, R Nishida, C Takashima, T Ohki, Y Shigematsu, F Watanabe, K Adachi, T Fukuyama, H Hamana, H Kishi, D Miura, Y Tanaka, K Onoue, K Onoguchi, Y Yamashita, R Stratford, T Clancy, R Yamaguchi, H Kuroda, K Doi, H Iwata, H Matsushita, "Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer." Journal for Immunotherapy of Cancer. 2023; 11(8): e007180.
Jul 27, 2023
Y Yamashita, "Utilization of Artificial Intelligence in vaccine development." 2023; The 39th Annual Meeting of the Japan Society of Drug Delivery System
Jun 6, 2023
Christian H.H. Ottensmeier, Jean-Pierre Delord, Ana Lalanne, Olivier Lantz, Camille Jamet, Annette TAVERNARO, Maud Brandely-Talbot, Benoît Grellier, Berangere Bastien, Hakim Makhloufi, Thierry Huss, Yoshiko Yamashita, Kousuke Onoue, Naoko Yamagata, Yuki Tanaka, Brandon Malone, Oliver Baker, Eric Quemeneur, Kaidre Bendjama, Christophe Le Tourneau. "Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma." ASCO. 2023; 6082-6082.
May 24, 2023
A Kitamura, "NEC's AI Drug Development Initiatives." 2023; 72nd SPSJ Annual Meeting
Apr 18, 2023
Ana Lalanne; Camille Jamet; Christian H. Ottensmeier; Jean-Pierre Delord; Christophe Le Tourneau; Matthew S. Block; Gerardo Colon-Otero; Keith L. Knutson; Annette Tavernaro; Gisele Lacoste; Benoit Grellier; Xavier Noiriel; Thierry Huss; Bernard Burtin; Yoshiko Yamashita; Kousuke Onoue; Kazuhide Onoguchi; Brandon Malone; Olivier Lantz; Oliver Baker; Naoko Yamagata; Yuki Tanaka; Eric Quemeneur; Maud Brandely; Kaidre Bendjama, "Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer." AACR. Cancer Research, 83(8_Supplement), LB205-LB205.
Jun 15, 2022
M Block, J Delord, C Ottensmeier, C Tourneau, A Lalanne, O Lantz, K Knutson, G Lacoste, A Tavernaro, M Brandely, N Silvestre, B Grellier, Y Yamashita, K Onoue, N Yamagata, E Quemeneur, and K Bendjama, "Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients." AACR. Cancer Research. 2022; 82(12 Suppl): CT182.
Jun 02, 2022
J Delord, M Block, C Ottensmeier, G Colon-Otero, C Tourneau, A Lalanne, C Jamet, O Lantz, K Knutson, G Lacoste, A Tavernaro, M Brandely-Talbot, N Silvestre, B Grellier, B Malone, Y Tanaka, K Onoue, Y Yamashita, E Quemeneur, and K Bendjama. "Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC)." ASCO. 2022; 2637-2637.
Jul 23, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 57th Annual Meeting of Liver Cancer Study Group of Japan
Jun 19, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 13th Annual Meeting of Japanese Society of Immunotherapy for Hematological Disorders
May 23, 2021
Y Yamashita, K Bendjama, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 18th Annual Meeting of Japan Research Association for Immunotherapeutics
Apr 16, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; Bring Innovation in the Pharmaceutical Industry
Mar 5, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 4th Social Smart Dental Hospital Symposium
Dec 23, 2020
B Malone, B Simovski, C Moliné, J Cheng, M Gheorghe, H Fontenelle, I Vardaxis, S Tennøe, JA Malmberg, R Stratford, and T Clancy, "Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs." Scientific reports. 2020; 10(1): 1-14.
Jun 22, 2020
B Malone, C Tosch, B Grellier, K Onoue, T Sztyler, K Rittner, Y Yamashita, E Quemeneur, and K Bendjama, "Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine." AACR. Cancer Research. 2020; 80(16 Suppl): 4566.
Mar 20, 2020
CLH Guerrero, Y Yamashita, M Miyara, N Imaizumi, M Kato, S Sakihama, M Hayashi, T Miyagi, K Karimata, J Uchihara, K Ohshiro, J Todoroki, S Nakachi, S Morishima, K Karube, Y Tanaka, H Masuzaki, and T Fukushima, "Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL." Blood advances. 2020; 4(6): 1062-1071.
Nov 29, 2019
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2019; The 32nd Annual Meeting of the Japan Society for Biological Therapy
Aug 23, 2019

K Onoue, Y Yamashita, B Malone, Y Tanaka, B Grellier, K Bendjama, K Machida, and K Udaka, "Evaluation of HLA-peptide binding prediction method." 2019; The 23rd Annual Meeting of Japanese Association of Cancer Immunology

Research Paper

NEC Labs Europe
Digital Health is a rapidly growing business for the NEC Group. In the Biomedical AI group, we consider challenges from prevention, diagnosis, and through treatment.

Read publication

NEC Labs America
Machine learning is the key technology for data analytics and artificial intelligence. We have been at the forefront of developments in such areas as deep learning, support vector machines and so on for over a decade.

Read publication

Contact